KALV

KalVista Pharmaceuticals, Inc. Common Stock

$26.87 +0.37%

Recent alerts on KALV

All signals →

Insider trade Sale by Piekos Brian (Chief Financial Officer)

Insider trade Sale by Sweeny Nicole (Chief Commercial Officer)

Insider trade Sale by Yea Christopher (CHIEF DEVELOPMENT OFFICER)

Insider trade Sale by Audhya Paul K. (CHIEF MEDICAL OFFICER)

Insider trade Sale by Palleiko Benjamin L (CHIEF EXECUTIVE OFFICER)

Insider trade Sale by Yea Christopher (CHIEF DEVELOPMENT OFFICER)

Insider trade Sale by Audhya Paul K. (CHIEF MEDICAL OFFICER)

Insider trade Sale by Palleiko Benjamin L (CHIEF EXECUTIVE OFFICER)

News KalVista Posts 154% Expense Jump in Q1

News Ionis Pharma Wins FDA Nod For First RNA-Targeted Therapy For Rare Genetic Swelling Disorder

Short volume Short volume 56% of volume (3.3σ)

Insider trade Sale by Benjamin L Palleiko (CHIEF EXECUTIVE OFFICER)

News Key deals this week: Organon, ARC Resources, Nebius, Eli Lilly and more

Scanner Large up move: 38.6% (2.9x normal daily movement)

News KalVista climbs as Italy’s Chiesi agrees to acquire in $1.9B deal

Scanner Unusual buy pressure (8.6x avg, 79% up-volume, +38.1% / +7.36 intraday, above VWAP)

News Chiesi Agrees to Buy KalVista Pharmaceuticals for $1.9 Billion

Short interest Short interest 38.4% of float

Insider trade Sale by Nicole Sweeny (Chief Commercial Officer)

Insider trade Sale by Paul K. Audhya (CHIEF MEDICAL OFFICER)

Insider trade Sale by Benjamin L Palleiko (CHIEF EXECUTIVE OFFICER)

Insider trade Sale by Brian Piekos (Chief Financial Officer)

Insider trade Sale by Nicole Sweeny (Chief Commercial Officer)

Insider trade Sale by Paul K. Audhya (CHIEF MEDICAL OFFICER)

Insider trade Sale by Benjamin L Palleiko (CHIEF EXECUTIVE OFFICER)

Get push alerts for KALV

Add it to your watchlist in the app and receive every signal the moment it fires.

Download for iOS

Download for iOS